Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Evaluating the prognostic value of PSMA PET/CT in mCRPC

Andrei Gafita, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, discusses the results of the multicenter, retrospective study of PSMA PET/CT as a prognostic tool in men with metastatic castration-resistant prostate cancer (mCRPC). The study aimed to establish the prognostic value of PSMA-imaging and response evaluation criteria to assess response to therapy. By comparing the tumor burden and the presence of lesions, PSMA PET/CT was able to predict overall survival. The results of the study have implications from an efficiency standpoint, but a randomized clinical trial is recommended to validate results. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.